Meeting
2016 ASCO Annual Meeting
IMpassion130: a Phase III randomized trial of atezolizumab with nab-paclitaxel for first-line treatment of patients with metastatic triple-negative breast cancer (mTNBC).
Authors
Leisha A. Emens
The Johns Hopkins University, Baltimore, MD
Leisha A. Emens , Sylvia Adams , Sherene Loi , Andreas Schneeweiss , Hope S. Rugo , Eric P. Winer , Carlos H. Barrios , Veronique Dieras , Juan de la Haba-Rodriguez , Luca Gianni , Stephen Y. Chui , Peter Schmid
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Triple-Negative Breast Cancer
Clinical Trial Registration Number
NCT02425891
Citation
J Clin Oncol 34, 2016 (suppl; abstr TPS1104)
DOI
10.1200/JCO.2016.34.15_suppl.TPS1104
Abstract #
TPS1104
Poster Bd #
205a
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Phase II COLET study: Atezolizumab (A) + cobimetinib (C) + paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC).
First Author: Adam Brufsky
Poster
2018 ASCO Annual Meeting
IMpassion132: A double-blind randomized phase 3 trial evaluating chemotherapy (CT) ± atezolizumab (atezo) for early progressing locally advanced/metastatic triple-negative breast cancer (mTNBC).
First Author: Rebecca Dent
Poster
2016 ASCO Annual Meeting
Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC).
First Author: Sylvia Adams
Poster
2016 ASCO Annual Meeting
Phase III clinical trials of atezolizumab combined with chemotherapy in chemotherapy-naive patients with advanced NSCLC.
First Author: Vassiliki Papadimitrakopoulou